Kynam Capital Management, LP - Q2 2023 holdings

Add to watchlist

$727 Million is the total value of Kynam Capital Management, LP's 26 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 0.0% .

All

		Value		Shares		↓ Weighting
AMRN	AMARIN CORP PLCspons adr new	$14,280,000	-20.7%	12,000,000	0.0%	1.96%	-15.5%
LQDA	LIQUIDIA CORPORATION	$12,891,615	+13.6%	1,642,244	0.0%	1.77%	+21.0%
CNTA	CENTESSA PHARMACEUTICALS PLCsponsored ads	$4,512,987	+60.8%	729,077	0.0%	0.62%	+71.5%
PBYI	PUMA BIOTECHNOLOGY INC	$1,669,937	+14.2%	473,070	0.0%	0.23%	+21.7%
RYTM	RHYTHM PHARMACEUTICALS INC	$1,527,007	-7.6%	92,602	0.0%	0.21%	-1.4%
NLTX	NEOLEUKIN THERAPEUTICS INC	$99,572	+18.6%	119,966	0.0%	0.01%	+27.3%
CBIO	CATALYST BIOSCIENCES INC	$31,604	+69.9%	89,886	0.0%	0.00%	+100.0%

Original filings

The following EDGAR filing(s) were analyzed to create this report:

View 13F-HR filed 2023-08-14

Signatures

The EDGAR filing(s) were signed by:

Robert Beinish — Compliance Consultant

Top long-term holdings

Name	Quarters owned	Latest quarter owned	Max weighting
SYNDAX PHARMACEUTICALS INC	8	Q3 2023	12.3%
CELLDEX THERAPEUTICS INC NEW	8	Q3 2023	14.4%
VAXCYTE INC	8	Q3 2023	10.9%
VERA THERAPEUTICS INC	8	Q3 2023	6.9%
TRAVERE THERAPEUTICS INC	8	Q3 2023	7.6%
VIRIDIAN THERAPEUTICS INC	8	Q3 2023	4.6%
BURNING ROCK BIOTECH LTD	8	Q3 2023	3.4%
AMARIN CORP PLC	8	Q3 2023	4.0%
LIQUIDIA CORPORATION	8	Q3 2023	3.6%
WAVE LIFE SCIENCES LTD	8	Q3 2023	3.7%

View Kynam Capital Management, LP's complete holdings history.

Latest filings

Type	Filed
13F-HR	2024-05-15
SC 13G/A	2024-03-08
13F-HR	2024-02-14
SC 13G/A	2024-02-14
SC 13G/A	2024-02-14
SC 13G/A	2024-02-14
SC 13G	2024-02-14
SC 13G	2024-02-14
SC 13G	2024-02-14
SC 13G	2024-02-14

View Kynam Capital Management, LP's complete filings history.

All filings

View complete filings history.

Export Kynam Capital Management, LP's holdings